cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Meiragtx Holdings Plc
2 own
4 watching
Current Price
$0
$-0.07
(-0.93%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
365.03M
52-Week High
52-Week High
11.575
52-Week Low
52-Week Low
4.77
Average Volume
Average Volume
0.03M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization365.03M
icon52-Week High11.575
icon52-Week Low4.77
iconAverage Volume0.03M
iconDividend Yield--
iconP/E Ratio--
What does the Meiragtx Holdings Plc do?
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson s diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
Read More
How much money does Meiragtx Holdings Plc make?
News & Events about Meiragtx Holdings Plc.
Globe Newswire
1month ago
LONDONandNEW YORK, April 21, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdingsplc(Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced two abstract presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting. The first ...
Globe Newswire
2 months ago
- Announced positive clinical data from AQUAx AAV-hAQP1 Phase 1 trial for treatment of Grade 2/3 Radiation-Induced Xerostomia in December 2022 - Announced positive top-line data from the MGT009 Phase 1/2 clinical study demonstrating safety and improvement in multiple domains of vision in X-linked ...
Globe Newswire
8 months ago
Results from the Phase 1/2 MGT009 study presented at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting set the stage for Phase 3 LUMEOS trial of botaretigene sparoparvovec in XLRP, which is actively dosing patientsLONDONandNEW YORK, Oct. 01, 2022 (GLOBE NEWSWIRE) -- MeiraGTx ...
Globe Newswire
8 months ago
--Manufacturing facilities built to accelerate development and delivery of advanced medicines to patients using state-of-the-art technology at scale, with quality appropriate for commercialization --Site reflects MeiraGTxs unique, end-to-end approach to gene therapy manufacturing to expedite ...
Globe Newswire
9 months ago
-- Recent Positive Topline Data from the Phase 1/2 Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) -- Financing Secured by Manufacturing Facilities Extends Cash Runway to Fourth Quarter 2024 LONDONandNEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE...
Frequently Asked Questions
Frequently Asked Questions
What is Meiragtx Holdings Plc share price today?
plus_minus_icon
Can Indians buy Meiragtx Holdings Plc shares?
plus_minus_icon
How can I buy Meiragtx Holdings Plc shares from India?
plus_minus_icon
Can Fractional shares of Meiragtx Holdings Plc be purchased?
plus_minus_icon
What are the documents required to start investing in Meiragtx Holdings Plc stocks?
plus_minus_icon
What is today’s traded volume of Meiragtx Holdings Plc?
plus_minus_icon
What is today’s market capitalisation of Meiragtx Holdings Plc?
plus_minus_icon
What is the 52-Week High and Low Range of Meiragtx Holdings Plc?
plus_minus_icon
What percentage is Meiragtx Holdings Plc down from its 52-Week High?
plus_minus_icon
What percentage is Meiragtx Holdings Plc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-0.07
(-0.93%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
ORCHARD THERAPEUTICS PLC
ORCHARD THERAPEUTICS PLC
$4.92
$-0.18 (-3.53 %)
IMMATICS NV
IMMATICS NV
$10.03
$-0.15 (-1.47 %)
GAMIDA CELL LTD
GAMIDA CELL LTD
$2.36
$-0.01 (-0.42 %)
AUTOLUS THERAPEUTICS PLC
AUTOLUS THERAPEUTICS PLC
$3.04
$0.14 (4.66 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
ORCHARD THERAPEUTICS PLC
ORCHARD THERAPEUTICS PLC
$4.92
$-0.18 (-3.53 %)
IMMATICS NV
IMMATICS NV
$10.03
$-0.15 (-1.47 %)
GAMIDA CELL LTD
GAMIDA CELL LTD
$2.36
$-0.01 (-0.42 %)
AUTOLUS THERAPEUTICS PLC
AUTOLUS THERAPEUTICS PLC
$3.04
$0.14 (4.66 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00